行情

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

实时行情|Nasdaq Last Sale

9.67
-0.03
-0.31%
交易中 15:11 11/21 EST
开盘
9.72
昨收
9.70
最高
9.81
最低
9.49
成交量
80.85万
成交额
--
52周最高
13.91
52周最低
6.26
市值
11.21亿
市盈率(TTM)
-8.8278
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SGMO 新闻

  • We're Keeping An Eye On Sangamo Therapeutics's (NASDAQ:SGMO) Cash Burn Rate
  • Simply Wall St..2天前
  • Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
  • Business Wire.2天前
  • Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
  • Business Wire.2天前
  • Edited Transcript of SGMO earnings conference call or presentation 6-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.11/14 11:59

更多

所属板块

生物技术和医学研究
-0.41%
制药与医学研究
+0.28%

热门股票

名称
价格
涨跌幅

SGMO 简况

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
展开

Webull提供Sangamo Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。